Patients were randomly assigned (1:1) to receive either three cycles of neoadjuvant pembrolizumab (200 mg intravenously [IV] every 3 weeks) followed by surgery and fifteen cycles of adjuvant pembrolizumab (n = 154 patients) or primary surgery followed by eighteen cycles of adjuvant pembrolizumab (n = 159 patients).[20] The primary end point was EFS in the intention-to-treat population
I dont want patients to feel like theyre choosing between the good option and the easy option, says Sajad Zalzala, MD, a board-certified family medicine physician and SkinnyRx medical advisor
Ideal for beginners or those on a budget
Dihexa: tested in a human, never
A 2009 review in the Journal of Biomaterials Science summarized GHK-Cu's capacity to upregulate collagen synthesis, stimulate elastin production, and increase glycosaminoglycan deposition in dermal tissue models
The oxidative stress of Hcy in the MTHFR genotype, the residual spike protein S in LC, and reactivated viruses due to persistent lymphopenia conspire to overwhelm mitochondria lacking an antioxidant shield